Moderna Generational Yolo Territory Part 3 and final.

AI Summary

Summary

Author’s thesis: Moderna (MRNA) is a “generational YOLO” and still undervalued despite a big run; price target is $250–$300.
He cites ~$60B market cap, Keytruda’s ~$20B annual revenue benchmark, a Merck profit-sharing agreement, and still-high short interest as setup for another squeeze.
He claims the recent pump was a gamma squeeze, not a short covering event, so a larger move could follow.

Quality assessment: Speculative retail DD with some valuation framing, but heavily reliant on squeeze mechanics, vague cancer-market assumptions, and an unclear drug (“intersimeran”) revenue outlook. Not institutional-grade research.

Score 174

Comments 72

Upvote % 94%

▶ Full Post Text

Ideas

u/VoidAndOcean Reddit r/wallstreetbets

Author argues MRNA’s market cap is still low relative to existing cancer-therapy revenue benchmarks and future cancer-market opportunity; short interest remains high. High short interest + valuation repricing potential creates a squeeze-friendly setup that could push MRNA toward the author’s $250–$300 target. Long MRNA as a momentum/valuation squeeze play, but the higher-conviction part of the thesis depends on speculative long-term drug revenue. Short squeezes can reverse sharply; clinical/regulatory setbacks; Merck profit-sharing limits per-drug economics; “intersimeran” revenue is speculative; author already banked $2.4M in profits.

Summary

▶ Full Post Text

Ideas

More from Reddit — r/wallstreetbets